At the Forefront of Care
Retina Associates has a team of researchers that are focused on advancing and improving the treatment of diseases of the retina, macula and vitreous through clinical studies, teaching, and development of new instruments and techniques. Our physicians have participated in a multitude of research studies and in many our physicians have served as principal investigators or co-investigators.
A study of intravitreal Iluvien Implant as Baseline Therapy in Patients with Early Diabetic Macular Edema.
This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.
This study evaluates OPT-302 with Aflibercept in Neovascular Age-related Macular Degeneration.
RGX-314 is being developed as a novel one-time gene therapy for the treatment of Neovascular Wet Age-Related Macular Degeneration as a potential one-time treatment for wet AMD.
A Phase 2 study of EYP-1901, a Tyrosine Kinase Inhibitor, compared to Sham for the improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy.
A Phase 2 study of EYP-1901, a Tyrosine Kinase Inhibitor, compared to Aflibercept in subjects with Wet Age-Related Macular Degeneration.
A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration.
A Randomized Clinical Trial evaluating Fenofibrate for prevention of Diabetic Retinopathy worsening.